MedPage Today (12/1, Bankhead) reported, “A novel immunotherapy provided durable disease control in homologous repair proficient (HRP) ovarian cancer, subgroup data from a small randomized trial showed.” After three years of surveillance, the “median overall survival (OS) had yet to be reached in patients who received gemogenovatucel-T (Vigil), but appeared to exceed 41 months, as compared with a median OS of 26.9 months for placebo-treated patients.” Additionally, “median recurrence-free survival (RFS) was almost twice as long with gemogenovatucel-T versus placebo.” Researchers found “restricted mean survival time (RMST) showed statistically significant improvement in OS and RFS in favor of patients who received the immunotherapy.” They concluded “the 3-year follow-up data support the safety and durable efficacy of gemogenovatucel-T and justify a phase III trial of maintenance therapy comparing the immunotherapy with bevacizumab and/or niraparib in patients with HRP ovarian cancer.”
